Abbott Laboratories $ABT Stock Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 83.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,387 shares of the healthcare product maker’s stock after selling 17,159 shares during the quarter. Simplify Asset Management Inc.’s holdings in Abbott Laboratories were worth $335,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in ABT. Foresight Capital Management Advisors Inc. acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Manning & Napier Advisors LLC purchased a new stake in Abbott Laboratories during the 2nd quarter worth $31,000. Balance Wealth Partners LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at $34,000. Summit Securities Group LLC increased its holdings in Abbott Laboratories by 41.3% in the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares in the last quarter. Finally, Addison Advisors LLC purchased a new position in Abbott Laboratories in the second quarter valued at about $40,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their target price for the company from $119.00 to $127.00 in a research note on Friday, October 2nd. Wells Fargo & Company raised their target price on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Finally, Robert W. Baird boosted their price target on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched a next-generation Oncodetect test designed to detect residual cancer disease, expanding its diagnostics portfolio and potentially supporting longer-term growth in oncology testing. Abbott Launches Next-Generation Oncodetect Test
• Positive Sentiment: The planned spin-off of Abbott’s Nutrition segment, which generates approximately $8.5 billion in annual sales, could allow the remaining company and the new standalone business to pursue more focused strategies. Abbott has appointed Daniel Salvadori to lead the future Nutrition company. What Could Abbott Laboratories Spin Off Mean for Its Future Growth?
• Positive Sentiment: Abbott received approximately $23.9 million in net ETF buying, indicating some continued institutional demand for ABT shares despite recent volatility. Abbott Sees $23.9 Million in Net ETF Buying
• Neutral Sentiment: Abbott is included in coverage of Europe’s medical foods market, which is projected to grow from $6.5 billion in 2026 to $7.9 billion by 2033. The outlook highlights a long-term opportunity for Abbott’s specialized nutrition business, though it does not represent new company-specific revenue. Europe Medical Foods Market Strategic Outlook
• Negative Sentiment: Argus Research downgraded Abbott from “Buy” to “Hold,” reportedly citing a guidance cut. The change removes a bullish rating catalyst and reinforces investor concerns about near-term demand and earnings visibility. Abbott Downgraded at Argus on Guidance Cut
• Negative Sentiment: Higher interest-rate expectations are creating pressure on richly valued quality-growth stocks such as Abbott, as elevated rates can reduce the value investors assign to future earnings. Demand headwinds and litigation risks are also cited as concerns. Abbott Demand Headwinds and Litigation Risks

Abbott Laboratories Trading Down 0.4%

ABT opened at $102.66 on Thursday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $177.64 billion, a PE ratio of 38.31, a P/E/G ratio of 1.82 and a beta of 0.59. The firm’s fifty day moving average price is $104.72 and its 200 day moving average price is $102.26.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the business earned $1.30 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 94.03%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.